Abilify, developed by Otsuka jointly with Bristol-Myers Squibb, was approved by the Food and Drug Administration (FDA) for treatment of acute manic and mixed episodes in children aged 10-17 associated with bipolar disorder.
The FDA has given the approval on the basis of four-week-study results. The drug showed effectiveness compared to a placebo.
The drug was first approved on November 15, 2002 for the treatment of schizophrenia, the sixth atypical antipsychotic medication of its kind in adults.
The behavior of the Russian inspector satellite, which was launched in the autumn of 2017, puzzles military officials in the United States
Ukrainian bloggers draw a parallel between the events in East Timor and the Crimea. Any comparison has a right to exist, but a detailed analysis of the situation does not give a promising forecast to Ukraine
Vladimir Putin is planning to attend the wedding ceremony of Austria's Foreign Minister Karin Kneissl on the way to Berlin